Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Preliminary experience with paclitaxel in advanced bladder cancer
B. J. Roth
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
26
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Preliminary experience with paclitaxel in advanced bladder cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Paclitaxel
100%
Advanced Bladder Cancer
100%
Diarrhea
16%
Neutropenia
16%
Neurotoxicity
16%
Nonhematologic
16%
Advanced Disease
16%
Granulocyte Colony-stimulating Factor (G-CSF)
16%
First-line Therapy
16%
Partial Response
16%
Conventional Chemotherapy
16%
Salvage Therapy
16%
Hematotoxicity
16%
Stable Disease
16%
Best Response
16%
Objective Response
16%
Continuous Infusion
16%
Eastern Cooperative Oncology Group
16%
Systemic Chemotherapy
16%
Bristol-Myers Squibb
16%
Febrile Neutropenia
16%
Combination Regimen
16%
Mucositis
16%
Agent Behavior
16%
Taxol
16%
Response Data
16%
Bladder Transitional Cell Carcinoma
16%
Princeton
16%
Advanced Urothelial Cancer
16%
Clinical Complete Response
16%
Medicine and Dentistry
Paclitaxel
100%
Bladder Cancer
100%
Diseases
28%
Neutropenia
14%
Diarrhea
14%
Bladder
14%
Oncology
14%
Salvage Therapy
14%
Continuous Infusion
14%
Febrile Neutropenia
14%
Transitional Cell Carcinoma
14%
Group Trial
14%
Granulocyte Colony Stimulating Factor
14%
Mucositis
14%
Urothelial Cancer
14%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Bladder Cancer
100%
Chemotherapy
28%
Diseases
28%
Malignant Neoplasm
14%
Diarrhea
14%
Neutropenia
14%
Granulocyte Colony Stimulating Factor
14%
Febrile Neutropenia
14%
Transitional Cell Carcinoma
14%
Mucosa Inflammation
14%
Group Trial
14%